TravelCenters of America Celebrates Driver Appreciation Month; Announces New Collaboration with Cleveland Clinic

TA to Provide Healthy Food Options and Wellness Resources for Professional Drivers WESTLAKE, Ohio–(BUSINESS WIRE)–As TravelCenters of America (Nasdaq: TA) celebrates Driver Appreciation Month in September, the company is demonstrating its commitment to professional drivers by providing more options to make healthy choices while on the road. TA announced a collaboration with Cleveland Clinic, one … [Read more…]

Moximed to Unveil Data from Pivotal Study of MISHA™ Knee System for First Time at Orthopaedic Summit (OSET) 2022

Two CME presentations and a lunch symposium will feature the world’s first implantable shock absorber (ISA) for knee osteoarthritis FREMONT, Calif.–(BUSINESS WIRE)–Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that David R. Diduch, MD, the A.F. Voshell Professor of Sports Medicine, … [Read more…]

Applied UV’s Airocide® and Lumicide Address CDC’s Recommendation for Handling Environments Contaminated by Monkeypox

MOUNT VERNON, N.Y.–(BUSINESS WIRE)–Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically affirms that its pathogen killing technology SteriLumen’s Airocide® and Lumicide are … [Read more…]

Osmind launches integrated virtual visits, expanding care options for in-demand mental health clinicians

Mental health clinicians treating patients with moderate to severe mental health conditions face increased demands on their time. The new Osmind virtual visit feature helps clinicians expand care in a variety of settings with built-in Zoom Video technology SAN FRANCISCO–(BUSINESS WIRE)–#ehr—Osmind, the public benefit corporation helping clinicians and researchers advance life-saving mental health treatment, today … [Read more…]

Researchers look at whether probiotics can slow osteoporosis in early menopause

Pendulum Therapeutics has teamed up with bone health researchers at Australian Catholic University to investigate the impact of a targeted probiotic formulation on bone, muscle, and glucose metabolism in early-stage menopause SAN FRANCISCO–(BUSINESS WIRE)–Pendulum Therapeutics, the biotech company pioneering the next frontier of health through their microbiome-targeted products, today announced Professor Mattias Lorentzon from the … [Read more…]

Carver Biosciences Launches with Seed Financing to Advance CRISPR/Cas13-based Technologies

BOSTON–(BUSINESS WIRE)–#cas13–Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the closure of a seed round of funding, led by Khosla Ventures. Carver is focused on using the bacterially derived RNA-directed RNase Cas13 to target respiratory viruses. The company was founded in 2021 by Dr. Cameron Myhrvold, Assistant Professor … [Read more…]

Diality Names Pamela Wapnick as Chief Financial Officer

Wapnick brings decades of financial experience to the company as it prepares for commercialization of its smart, mobile hemodialysis platform IRVINE, Calif.–(BUSINESS WIRE)–Diality Inc., a medical technology company developing a smart, mobile hemodialysis platform, today announced the hiring of Pamela Wapnick as chief financial officer. She brings to the company more than 30 years of … [Read more…]

Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today preliminary Phase 1 data supporting the … [Read more…]

Humana Introduces Mid-Term Adjusted EPS Target of $37 in 2025 and Raises Full Year 2022 Adjusted EPS Financial Guidance to ‘approximately $25’ at Investor Day

Introduces a mid-term Adjusted EPS target of $37.00 per diluted common share for the year ending December 31, 2025, representing a compelling 14 percent compounded annual growth rate over the company’s updated FY 2022 Adjusted EPS outlook Expects to deliver continued earnings growth in 2026 and beyond at or above the EPS growth trends reflected … [Read more…]

Kurin, Inc. Provides Update on Litigation Activity

SAN DIEGO–(BUSINESS WIRE)–Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, provides an update to the most recent moves by Magnolia Medical Technologies. This week, Magnolia filed a motion in the US District Court of Delaware for a permanent injunction, hoping to take Kurin off the market. “We are disappointed, but … [Read more…]